Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies

Abstract

Key points:

Keywords

cell-free DNA methylation / circulating tumour cells (CTCs) / circulating tumour DNA (ctDNA) / early cancer detection / extracellular vesicles/exosomes / fragmentomics / gastrointestinal cancers / liquid biopsy / multi-cancer early detection (MCED) / tumour-educated platelets (TEPs)

References

[1] Li M, Cao S, Xu RH. Global trends and epidemiological shifts in gastrointestinal cancers: insights from the past four decades. Cancer Commun (Lond). 2025; 45(7): 774-788.

[2] Januszewicz W, Nowicki-Osuch K. Novel devices and biomarkers in screening for esophageal squamous cell cancer. Best Pract Res Clin Gastroenterol. 2025; 75:102005.

[3] Zhang Y, Wang X, Sh KMI, et al. Early diagnosis of colorectal cancer via plasma-derived SDC2, KCNQ5, and IKZF1 methylation levels. Clin Lab. 2025; 71(3).

[4] Gao Y, Cao D, Li M, et al. Integration of multiomics features for blood-based early detection of colorectal cancer. Mol Cancer. 2024; 23(1): 173.

[5] Wehrle CJ, Raj R, Aykun N, et al. Liquid biopsy by ctDNA in liver transplantation for colorectal cancer liver metastasis. J Gastrointest Surg. 2023; 27(7): 1498-1509.

[6] Loomans-Kropp HA, Song Y, Gala M, et al. Methylated Septin9 (mSEPT9): a promising blood-based biomarker for the detection and screening of early-onset colorectal cancer. Cancer Res Commun. 2022; 2(2): 90-98.

[7] Shield Blood Test Approved for Colorectal Cancer Screening—NCI. 2024. Accessed December 23, 2025. https://www.cancer.gov/news-events/cancer-currents-blog/2024/shield-blood-test-colorectal-cancer-screening

[8] Colon Health Alert: FDA Approves New Screening Test Epi proColon | Colorectal Cancer Alliance. 2016. Accessed December 26, 2025. https://colorectalcancer.org/article/colon-health-alert-fda-approves-new-screening-test-epi-procolon

[9] Rahadiani N, Stephanie M, Manatar AF, Krisnuhoni E. The diagnostic utility of cfDNA and ctDNA in liquid biopsies for gastrointestinal cancers over the last decade. Oncol Res Treat. 2024; 48(3): 125-141.

[10] Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018; 359(6378): 926-930.

[11] FDA Clears Test for Monitoring Metastatic Colorectal Cancer | CancerNetwork. 2025. Accessed December 26, 2025. https://www.cancernetwork.com/view/fda-clears-test-monitoring-metastatic-colorectal-cancer

[12] Thanh Huong P, Gurshaney S, Thanh Binh N, et al. Emerging role of circulating tumor cells in gastric cancer. Cancers (Basel). 2020; 12(3): 695.

[13] Dahiya DS, Malik S, Paladiya R, et al. Advances in non-invasive screening methods for gastrointestinal cancers: how continued innovation has revolutionized early cancer detection. Cancers. 2025; 17(7): 1085.

[14] Xu Q, Yan Q, Dai Z, et al. Diagnostic value of exosome non-coding RNAs as non-invasive biomarkers in gastric cancer: a meta-analysis. Front Oncol. 2025; 15:1570020.

[15] Sui S, Xu C, Kanda M, et al. Exosomal liquid biopsy for the early detection of gastric cancer: the DESTINEX multicenter study. JAMA Surg. 2025; 160(9): 973-982.

[16] Fabbricatore R. Accessed December 26, 2025. 2025. https://www.cancernetwork.com/view/fda-grants-evoliver-biopsy-test-breakthrough-device-designation-for-hcc

[17] Yan R, Chen H, Selaru FM. Extracellular vesicles in hepatocellular carcinoma: progress and challenges in the translation from the laboratory to clinic. Medicina (Kaunas). 2023; 59(9): 1599.

[18] Yang L, Jiang Q, Li DZ, Zhou X, Yu DS, Zhong J. TIMP1 mRNA in tumor-educated platelets is diagnostic biomarker for colorectal cancer. Aging (Albany NY). 2019; 11(20): 8998-9012.

[19] Han DM, Wakefield MR, Fang Y. Beyond detection: conventional and emerging biomarkers in gastrointestinal cancers. Cancers (Basel). 2025; 17(17): 2725.

[20] Tie J, Wang Y, Lo SN, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025; 31(5): 1509-1518.

[21] David P, Mittelstädt A, Kouhestani D, et al. Current applications of liquid biopsy in gastrointestinal cancer disease-from early cancer detection to individualized cancer treatment. Cancers (Basel). 2023; 15(7): 1924.

[22] Moati E, Taly V, Garinet S, et al. Role of circulating tumor DNA in gastrointestinal cancers: current knowledge and perspectives. Cancers (Basel). 2021; 13(19): 4743.

[23] Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022; 132(12):e154941.

[24] Salehnia Z, Rezaee D, Ehtiati S, Bakhtiari M, Khalilzad MA, Najafi S. Liquid biopsy for the management of gastrointestinal cancers. Clin Chim Acta. 2026; 578:120474.

[25] Grizzi G, Salati M, Bonomi M, et al. Circulating tumor DNA in gastric adenocarcinoma: future clinical applications and perspectives. Int J Mol Sci. 2023; 24(11): 9421.

[26] Chung J, Xiao S, Gao Y, Soung YH. Recent technologies towards diagnostic and therapeutic applications of circulating nucleic acids in colorectal cancers. Int J Mol Sci. 2024; 25(16): 8703.

[27] Yedid N, Kalma Y, Malcov M, et al. The effect of a germline mutation in the APC gene on β-catenin in human embryonic stem cells. BMC Cancer. 2016; 16(1): 952.

[28] Bruschi M, Garnier L, Cleroux E, et al. Loss of Apc rapidly impairs DNA methylation programs and cell fate decisions in Lgr5+ intestinal stem cells. Cancer Res. 2020; 80(11): 2101-2113.

[29] Davidson LA, Callaway E, Kim E, et al. Targeted deletion of p53 in Lgr5-expressing intestinal stem cells promotes colon tumorigenesis in a preclinical model of colitis-associated cancer. Cancer Res. 2015; 75(24): 5392-5397.

[30] Branca JA, Low BE, Saxl RL, et al. Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice. Genes Cancer. 2020; 11(1-2): 83-94.

[31] Fang B. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochim Biophys Sin (Shanghai). 2016; 48(1): 27-38.

[32] Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Mol Cancer Res. 2012; 10(9): 1228-1239.

[33] Haddadi N, Lin Y, Travis G, Simpson AM, Nassif NT, McGowan EM. PTEN/PTENP1: “Regulating the regulator of RTK-dependent PI3K/Akt signalling”, new targets for cancer therapy. Mol Cancer. 2018; 17(1): 37.

[34] Sato M, Rodriguez-Barrueco R, Yu J, Do C, Silva JM, Gautier J. MYC is a critical target of FBXW7. Oncotarget. 2015; 6(5): 3292-3305.

[35] Neumeyer V, Grandl M, Dietl A, et al. Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells. Carcinogenesis. 2019; 40(4): 551-559.

[36] Malkawi W, Lutfi A, Afghan MK, et al. Circulating tumour cell enumeration, biomarker analyses, and kinetics in patients with colorectal cancer and other GI malignancies. Front Oncol. 2023; 13:1305181.

[37] Tan K, Zhu H, Ma X. Liquid biopsy of circulating tumor cells: from isolation, enrichment, and genome sequencing to clinical applications. Histol Histopathol. 2025; 40(10): 1529-1546.

[38] Zhang Z, Wu H, Chong W, Shang L, Jing C, Li L. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers. Cell Death Dis. 2022; 13(10): 903.

[39] Bazan Russo TD, Pepe F, Gristina V, et al. Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer. Future Oncol. 2025; 21(21): 2803-2821.

[40] Yang C, Chen F, Wang S, Xiong B. Circulating tumor cells in gastrointestinal cancers: current status and future perspectives. Front Oncol. 2019; 9: 1427.

[41] Wullaert L, Jansen MPHM, Kraan J, et al. Circulating tumour cells & circulating tumour DNA in patients with resectable colorectal liver metastases (MIRACLE): a prospective, observational biomarker study. EClinicalMedicine. 2025; 87:103406.

[42] Kanayama M, Yoneda K, Kuwata T, et al. Enhanced capture system for mesenchymal‑type circulating tumor cells using a polymeric microfluidic device “CTC‑Chip” incorporating cell‑surface vimentin. Oncol Rep. 2024; 52(5): 156.

[43] Yang C, Zhang N, Wang S, et al. Wedge-shaped microfluidic chip for circulating tumor cells isolation and its clinical significance in gastric cancer. J Transl Med. 2018; 16(1): 139.

[44] Dai CS, Mishra A, Edd J, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: blood-based detection, molecular biology, and clinical applications. Cancer Cell. 2025; 43(8): 1399-1422.

[45] Javdani-Mallak A, Mowla SJ, Alibolandi M. Tumor-derived exosomes and their application in cancer treatment. J Transl Med. 2025; 23(1): 751.

[46] Wang S, Dong Y, Gong A, et al. Exosomal circRNAs as novel cancer biomarkers: challenges and opportunities. Int J Biol Sci. 2021; 17(2): 562-573.

[47] Salehi M, Sharifi M. Exosomal miRNAs as novel cancer biomarkers: challenges and opportunities. J Cell Physiol. 2018; 233(9): 6370-6380.

[48] Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015; 523(7559): 177-182.

[49] Yu J, Ostowari A, Gonda A, et al. Exosomes as a source of biomarkers for gastrointestinal cancers. Cancers (Basel). 2023; 15(4): 1263.

[50] Feng R, Yin Y, Wei Y, et al. Mutant p53 activates hnRNPA2B1-AGAP1-mediated exosome formation to promote esophageal squamous cell carcinoma progression. Cancer Lett. 2023; 562:216154.

[51] Yang YC, Liu GJ, Yuan DF, Li CQ, Xue M, Chen LJ. Influence of exosome-derived miR-21on chemotherapy resistance of esophageal cancer. Eur Rev Med Pharmacol Sci. 2019; 23(4): 1513-1519.

[52] Ferrari PA, Salis CB, Macciò A. Current evidence supporting the role of miRNA as a biomarker for lung cancer diagnosis through exhaled breath condensate collection: a narrative review. Life (Basel). 2025; 15(5): 683.

[53] Cherchi R, Cusano R, Orrù S, et al. Next generation sequencing for miRNA detection on the exhaled breath condensate: a pilot study. Epigenet Insights. 2023; 16:25168657231160985.

[54] Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med. 2015; 8(7): 11683-11691.

[55] Lee KJ, Yi SW, Chung MJ, et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013; 54(3): 643-649.

[56] Poruk KE, Gay DZ, Brown K, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013; 13(3): 340-351.

[57] Sekiguchi M, Matsuda T. Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening. Sci Rep. 2020; 10(1):18202.

[58] Zhao B, Zhao B, Chen F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022; 34(9): 891-904.

[59] Trapé J, Fernández-Galán E, Auge JM, et al. Factors influencing blood tumor marker concentrations in the absence of neoplasia. Tumour Biol. 2024; 46(s1): S35-S63.

[60] Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer. 2021; 1875(2):188409.

[61] Wang Y, Zhang H, Li H, Xiong J, Wang J, Huang Y. Application of tumor-educated platelets as new fluid biopsy markers in various tumors. Clin Transl Oncol. 2023; 25(1): 114-125.

[62] Denis JA, Guillerm E, Coulet F, Larsen AK, Lacorte JM. The role of BEAMing and digital PCR for multiplexed analysis in molecular oncology in the era of next-generation sequencing. Mol Diagn Ther. 2017; 21(6): 587-600.

[63] Abou Daya S, Mahfouz RAR, Circulating tumor DNA, liquid biopsy, and next generation sequencing: a comprehensive technical and clinical applications review. 2018 Meta Gene 17 Published online 2018.

[64] Esposito Abate R, Frezzetti D, Maiello MR, et al. Next generation sequencing-based profiling of cell free DNA in patients with advanced non-small cell lung cancer: advantages and pitfalls. Cancers (Basel). 2020; 12(12): 3804.

[65] Mo S, Ye L, Wang D, et al. Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation. JAMA Oncol. 2023; 9(6): 770-778.

[66] Song L, Wang J, Wang H, et al. The quantitative profiling of blood mSEPT9 determines the detection performance on colorectal tumors. Epigenomics. 2018; 10(12): 1569-1583.

[67] Jamshidi A, Liu MC, Klein EA, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell. 2022; 40(12): 1537-1549.e12.

[68] Bure IV, Nemtsova MV. Methylation and noncoding RNAs in gastric cancer: everything is connected. Int J Mol Sci. 2021; 22(11): 5683.

[69] Guo XJ, Huang XY, Yang X, et al. Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis. Cell Death Dis. 2023; 14(2): 79.

[70] Kalra A, Ma K, Cheng Y, et al. Discovery of methylated DNA biomarkers for potential nonendoscopic detection of barrett's esophagus and esophageal adenocarcinoma. Am J Gastroenterol. 2025; 120(10): 2268-2279.

[71] Huang A, Guo DZ, Su ZX, et al. GUIDE: a prospective cohort study for blood-based early detection of gastrointestinal cancers using targeted DNA methylation and fragmentomics sequencing. Mol Cancer. 2025; 24(1): 163.

[72] Yuan SQ, Nie RC, Huang YS, et al. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Cancer Commun (Lond). 2023; 43(12): 1312-1325.

[73] Acheampong E, Abed A, Morici M, et al. Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer. Transl Lung Cancer Res. 2022; 11(3): 440-451.

[74] Zhou Z, Lin T, Chen S, et al. Omics-based molecular classifications empowering in precision oncology. Cell Oncol (Dordr). 2024; 47(3): 759-777.

[75] Buchanan AH, Lennon AM, Choudhry OA, et al. Multiyear clinical outcomes of cancers diagnosed following detection by a blood-based multicancer early detection test. Cancer Prev Res (Phila). 2024; 17(8): 349-353.

[76] Hoare M, Fitzgerald RC. What is the current status of multicancer early detection tests and upper gastrointestinal cancer?. Lancet Gastroenterol Hepatol. 2023; 8(12): 1065-1066.

[77] Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun (Lond). 2021; 41(12): 1257-1274.

[78] Brett AllenS. Accessed November 14, 2025. https://www.jwatch.org/na58018/2024/10/10/fda-approves-new-options-colorectal-cancer-screening

[79] Brenne SS, Madsen PH, Pedersen IS, et al. Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study. Br J Cancer. 2023; 129(5): 861-868.

[80] Yamada A, Horimatsu T, Okugawa Y, et al. Serum miR-21, miR-29a, and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res. 2015; 21(18): 4234-4242.

[81] Ren J, Lu P, Zhou X, et al. Genome-scale methylation analysis of circulating cell-free DNA in gastric cancer patients. Clin Chem. 2022; 68(2): 354-364.

[82] Ma Y, Zhao G, Wang K, et al. Clinical performance of a liquid biopsy test based on the detection of multiple DNA methylation biomarkers for early detection of gastrointestinal cancers. J Clin Oncol. 2022; 40(16): e16096-e16096. suppl.

[83] Guo X, Lv X, Ru Y, et al. Circulating exosomal gastric cancer-associated long noncoding RNA1 as a biomarker for early detection and monitoring progression of gastric cancer: a multiphase study. JAMA Surg. 2020; 155(7): 572-579.

[84] Guo X, Peng Y, Song Q, et al. A liquid biopsy signature for the early detection of gastric cancer in patients. Gastroenterology. 2023; 165(2): 402-413.e13.

[85] Mencel J, Slater S, Cartwright E, Starling N. The role of ctDNA in gastric cancer. Cancers (Basel). 2022; 14(20): 5105.

[86] Miyoshi J, Mannucci A, Scarpa M, et al. Liquid biopsy to identify Barrett's oesophagus, dysplasia and oesophageal adenocarcinoma: the EMERALD multicentre study. Gut. 2025; 74(2): 169-181.

[87] Tai D, Latif K, Shah P, et al. Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA. Front Oncol. 2025; 15:1622984.

[88] Zheng Y, Xing W, BingWei null, et al. Detection of a novel DNA methylation marker panel for esophageal cancer diagnosis using circulating tumor DNA. BMC Cancer. 2024; 24(1): 1578.

[89] Iwaya T, Endo F, Takahashi F, Tokino T, Sasaki Y, Nishizuka SS. Frequent tumor burden monitoring of esophageal squamous cell carcinoma with circulating tumor DNA using individually designed digital polymerase chain reaction. Gastroenterology. 2021; 160(1): 463-465.e4.

[90] Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 2012; 31(1): 38.

[91] Filipów S, Łaczmański Ł. Blood circulating miRNAs as cancer biomarkers for diagnosis and surgical treatment response. Front Genet. 2019; 10: 169.

[92] Tong YS, Wang XW, Zhou XL, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer. 2015; 14: 3.

[93] Xu YW, Peng YH, Xu LY, Xie JJ, Li EM. Autoantibodies: potential clinical applications in early detection of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma. World J Gastroenterol. 2019; 25(34): 5049-5068.

[94] Sun J, Awad MA, Hwang J, Villano AM. Molecular biomarkers for the diagnosis and prognostication of pancreatic ductal adenocarcinoma. J Pers Med. 2025; 15(6): 236.

[95] Uddin MH, MN Al-Hallak, Philip PA, et al. Exosomal microRNA in pancreatic cancer diagnosis, prognosis, and treatment: from bench to bedside. Cancers (Basel). 2021; 13(11): 2777.

[96] Engels MML, Berger CK, Mahoney DW, et al. Multimodal pancreatic cancer detection using methylated DNA biomarkers in pancreatic juice and plasma CA 19-9: a prospective multicenter study. Clin Gastroenterol Hepatol. 2025; 23(5): 766-775.

[97] Jin D, Qian L, Chen J, Yu Z, Dong J. Diagnostic accuracy of methylated SEPT9 for primary liver cancer: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025; 16:1434174.

[98] Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol. 2011; 91(3): 702-707.

[99] Arvind A, Singal AG. Emerging liquid biopsy techniques for early detection of hepatocellular carcinoma, prognostication, and disease monitoring. Clin Liver Dis (Hoboken). 2022; 20(1): 18-20.

[100] Han JY, Ahn KS, Kim TS, et al. Liquid biopsy from bile-circulating tumor DNA in patients with biliary tract cancer. Cancers (Basel). 2021; 13(18): 4581.

[101] Selaru FM, Olaru AV, Kan T, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009; 49(5): 1595-1601.

[102] Shirley M. Epi proColon® for colorectal cancer screening: a profile of its use in the USA. Mol Diagn Ther. 2020; 24(4): 497-503.

[103] Riva F, Dronov OI, Khomenko DI, et al. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol. 2016; 10(3): 481-493.

[104] Miller SJ, Sly JR, Rolfo C, et al. Multi-cancer early detection (MCED) tests: prioritizing equity from bench to bedside. Health Aff Sch. 2024; 2(5):qxae039.

[105] Imai M, Nakamura Y, Yoshino T. Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies. Int J Clin Oncol. 2025; 30(2): 180-193.

[106] Yay Donderici E, Forbes SP, Zhang NJ, et al. Cost-effectiveness of blood-based colorectal cancer screening—a simulation model incorporating real-world longitudinal adherence. Expert Rev Pharmacoecon Outcomes Res. 2025; 25(5): 671-677.

[107] Ziranu P, Pretta A, Saba G, et al. Navigating the landscape of liquid biopsy in colorectal cancer: current insights and future directions. Int J Mol Sci. 2025; 26(15): 7619.

[108] Chiarello MM, Fico V, Pepe G, et al. Early gastric cancer: a challenge in Western countries. World J Gastroenterol. 2022; 28(7): 693-703.

[109] Ding P, Wu H, Wu J, et al. Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer. J Exp Clin Cancer Res. 2024; 43(1): 181.

[110] Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res. 2018; 24(24): 6248-6256.

[111] Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res. 2019; 25(23): 7098-7112.

[112] Chen X, Li X, Peng X, et al. Use of a four-miRNA panel as a biomarker for the diagnosis of stomach adenocarcinoma. Dis Markers. 2020; 2020:8880937.

[113] So JBY, Kapoor R, Zhu F, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. Gut. 2021; 70(5): 829-837.

[114] Yu P, Chen P, Wu M, et al. Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer. Genome Med. 2024; 16(1): 79.

[115] Izumi D, Zhu Z, Chen Y, et al. Assessment of the diagnostic efficiency of a liquid biopsy assay for early detection of gastric cancer. JAMA Netw Open. 2021; 4(8):e2121129.

[116] Qu HT, Li Q, Hao L, et al. Esophageal cancer screening, early detection and treatment: current insights and future directions. World J Gastrointest Oncol. 2024; 16(4): 1180-1191.

[117] Lam RCT, Johnson D, Lam G, et al. Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers—current evidence and future directions. Front Oncol. 2022; 12:970242.

[118] Wang L, Ji F, Liu G, et al. Upregulation of circulating miR130a is correlated with development of Barrett's esophagus and esophageal adenocarcinoma. Onco Targets Ther. 2019; 12: 1-7.

[119] Weaver JP. Affirming physicians’ professionalism against the destructive influence of private third party relations. Durham-Orange County resolutions. N C Med J. 1991; 52(11): 587-589.

[120] Iacob R, Mandea M, Iacob S, et al. Liquid biopsy in squamous cell carcinoma of the esophagus and of the head and neck. Front Med (Lausanne). 2022; 9:827297.

[121] Hoshi Y, Matsuda S, Takeuchi M, Kawakubo H, Kitagawa Y. Liquid biopsy and multidisciplinary treatment for esophageal cancer. Cancers (Basel). 2025; 17(2): 196.

[122] Koltai T. Earlier diagnosis of pancreatic cancer: is it possible?. Cancers (Basel). 2023; 15(18): 4430.

[123] Reese KL, Pantel K, Smit DJ. Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer—a comprehensive review. J Exp Clin Cancer Res. 2024; 43(1): 250.

[124] Qin C, Li T, Lin C, et al. The systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapy. Cancer Cell Int. 2024; 24(1): 264.

[125] Chi H, Shi L, Gan S, Fan G, Dong Y. Innovative applications of nanopore technology in tumor screening: an exosome-centric approach. Biosensors (Basel). 2025; 15(4): 199.

[126] Hong H, Wehrle CJ, Karakaya OF, et al. Circulating tumor DNA in primary and secondary liver cancers: a comprehensive review. Front Biosci (Schol Ed). 2025; 17(2):26972.

[127] Wehrle CJ, Hong H, Kamath S, et al. Tumor mutational burden from circulating tumor DNA predicts recurrence of hepatocellular carcinoma after resection: an emerging biomarker for surveillance. Ann Surg. 2024; 280(3): 504-513.

[128] Lin N, Lin Y, Xu J, et al. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol Commun. 2022; 6(7): 1753-1763.

[129] Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019; 68(12): 2195-2205.

[130] Wei XY, Ding J, Tian WG, Yu YC. MicroRNA-122 as a diagnostic biomarker for hepatocellular carcinoma related to hepatitis C virus: a meta-analysis and systematic review. J Int Med Res. 2020; 48(8):300060520941634.

[131] Lin SY, Xia W, Kim AK, et al. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma. Sci Rep. 2023; 13(1):21585.

[132] Polpichai N, Maneenil C, Danpanichkul P, et al. Current and new strategies for hepatocellular carcinoma surveillance. Gastroenterol Rep (Oxf). 2025; 13:goaf045.

[133] Dadgar N, Arunachalam AK, Hong H, et al. Advancing cholangiocarcinoma care: insights and innovations in T cell therapy. Cancers (Basel). 2024; 16(18): 3232.

[134] Wang Y, Li Y, Liang Z, et al. Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives. Front Cell Dev Biol. 2025; 13:1616064.

[135] Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteomics. 2020; 17(5): 441-452.

[136] Arrichiello G, Nacca V, Paragliola F, Giunta EF. Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives. Explor Target Antitumor Ther. 2022; 3(3): 362-374.

[137] Kim KH, Yi HS, Lee H, Bae GE, Yeo MK. Targeting the sequences of circulating tumor DNA of cholangiocarcinomas and its applications and limitations in clinical practice. Int J Mol Sci. 2023; 24(8): 7512.

[138] Gou Q, Zhang CZ, Sun ZH, et al. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer. ESMO Open. 2021; 6(6):100275.

[139] Wasenang W, Chaiyarit P, Proungvitaya S, Limpaiboon T. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clin Epigenetics. 2019; 11(1): 39.

[140] Guardant Health's ShieldTM Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening. AdvaMed®. 2024. Accessed November 14, 2025. https://www.advamed.org/industry-updates/news/guardant-healths-shield-blood-test-approved-by-fda-as-a-primary-screening-option-clearing-path-for-medicare-reimbursement-and-a-new-era-of-colorectal-cancer-screening/

[141] Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023; 402(10409): 1251-1260.

[142] Boeri M, Signoroni S, Ciniselli CM, et al. Detection of (pre)cancerous colorectal lesions in Lynch syndrome patients by microsatellite instability liquid biopsy. Cancer Gene Ther. 2024; 31(6): 842-850.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.